Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark S Sands

Showing results (91-100 of 105) with videos related to

Pageof 11
Sort By:
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 8, 2011
Bone marrow transplantation augments the effect of brain- and spinal cord-directed adeno-associated virus 2/5 gene therapy by altering inflammation in the murine model of globoid-cell leukodystrophyAdarsh S Reddy, Joong H Kim, Jacqueline A Hawkins-Salsbury, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 3, 2021
Enhanced Efficacy and Increased Long-Term Toxicity of CNS-Directed, AAV-Based Combination Therapy for Krabbe DiseaseYedda Li, Christopher A Miller, Lauren K Shea, et al.
JCI Insight|August 21, 2025
GABAergic interneurons contribute to the fatal seizure phenotype of CLN2 disease miceKeigo Takahashi, Nicholas R Rensing, Elizabeth M Eultgen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2021
Waning efficacy in a long-term AAV-mediated gene therapy study in the murine model of Krabbe diseaseGregory J Heller, Michael S Marshall, Yazan Issa, et al.
Acta Neuropathologica Communications|July 23, 2025
Gene therapy ameliorates neuromuscular pathology in CLN3 diseaseEwa A Ziółkowska, Albina Jablonka-Shariff, Letitia L Williams, et al.
Scientific Reports|July 15, 2021
Substrate reduction therapy for Krabbe disease and metachromatic leukodystrophy using a novel ceramide galactosyltransferase inhibitorMichael C Babcock, Christina R Mikulka, Bing Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 19, 2019
Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic targetYedda Li, Yue Xu, Bruno A Benitez, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Haploinsufficiency of lysosomal enzyme genes in Alzheimer's diseaseBruno A Benitez, Clare E Wallace, Maulikkumar Patel, et al.
Biorxiv : the Preprint Server for Biology|February 20, 2025
Identifying and treating CLN3 disease outside the central nervous systemEwa A Ziółkowska, Albina Jablonka-Shariff, Letitia L Williams, et al.
The Journal of Clinical Investigation|August 11, 2020
Krabbe disease successfully treated via monotherapy of intrathecal gene therapyAllison M Bradbury, Jessica H Bagel, Duc Nguyen, et al.
Pageof 11

Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 8, 2011
Bone marrow transplantation augments the effect of brain- and spinal cord-directed adeno-associated virus 2/5 gene therapy by altering inflammation in the murine model of globoid-cell leukodystrophyAdarsh S Reddy, Joong H Kim, Jacqueline A Hawkins-Salsbury, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 3, 2021
Enhanced Efficacy and Increased Long-Term Toxicity of CNS-Directed, AAV-Based Combination Therapy for Krabbe DiseaseYedda Li, Christopher A Miller, Lauren K Shea, et al.
JCI Insight|August 21, 2025
GABAergic interneurons contribute to the fatal seizure phenotype of CLN2 disease miceKeigo Takahashi, Nicholas R Rensing, Elizabeth M Eultgen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2021
Waning efficacy in a long-term AAV-mediated gene therapy study in the murine model of Krabbe diseaseGregory J Heller, Michael S Marshall, Yazan Issa, et al.
Acta Neuropathologica Communications|July 23, 2025
Gene therapy ameliorates neuromuscular pathology in CLN3 diseaseEwa A Ziółkowska, Albina Jablonka-Shariff, Letitia L Williams, et al.
Scientific Reports|July 15, 2021
Substrate reduction therapy for Krabbe disease and metachromatic leukodystrophy using a novel ceramide galactosyltransferase inhibitorMichael C Babcock, Christina R Mikulka, Bing Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 19, 2019
Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic targetYedda Li, Yue Xu, Bruno A Benitez, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Haploinsufficiency of lysosomal enzyme genes in Alzheimer's diseaseBruno A Benitez, Clare E Wallace, Maulikkumar Patel, et al.
Biorxiv : the Preprint Server for Biology|February 20, 2025
Identifying and treating CLN3 disease outside the central nervous systemEwa A Ziółkowska, Albina Jablonka-Shariff, Letitia L Williams, et al.
The Journal of Clinical Investigation|August 11, 2020
Krabbe disease successfully treated via monotherapy of intrathecal gene therapyAllison M Bradbury, Jessica H Bagel, Duc Nguyen, et al.
Pageof 11